AAV Contract Development And Manufacturing Organizations Market Size, Share & Trends Analysis Report By Workflow (Upstream Processing, Downstream Processing), By Culture, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
Description
AAV Contract Development And Manufacturing Organizations Market Summary
The global AAV contract development and manufacturing organizations market size was estimated at USD 862.7 million in 2024 and is projected to reach USD 3,490.3 million by 2033, growing at a CAGR of 16.50% from 2025 to 2033. The market is driven due to the rising demand for adeno-associated virus (AAV) vectors in gene therapy applications, particularly in the treatment of rare genetic disorders, ophthalmic conditions, and neurological diseases.
Increasing approvals of AAV-based therapies by regulatory bodies have further accelerated the need for specialized manufacturing capacity. The market is primarily driven by thesurge in R&D investments in cell and gene therapy pipelines and is also fueling the reliance on AAV CDMOs. Small and mid-sized biotech firms often lack in-house vector development capabilities, making outsourcing a cost-effective and efficient solution. Leading CDMOs are expanding their capabilities by building advanced viral vector manufacturing facilities, integrating automated platforms, and offering end-to-end services including process development, GMP manufacturing, and regulatory support. This expansion of service portfolios is creating strong growth opportunities for the market.
To learn more about this report, request a free sample copy
Furthermore, strategic partnerships and capacity expansions by key players such as Lonza, Catalent, Thermo Fisher Scientific, and Samsung Biologics are enhancing market competitiveness. The growing prevalence of genetic and rare diseases, coupled with an increasing number of clinical trials evaluating AAV-based therapies, is further driving outsourcing demand. These dynamics position AAV CDMOs as a critical backbone of the gene therapy ecosystem, ensuring a timely supply of high-quality viral vectors for both clinical and commercial use.
Global AAV Contract Development And Manufacturing Organizations Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AAV contract development and manufacturing organizations market report based on workflow, culture, application, end use, and region.
The global AAV contract development and manufacturing organizations market size was estimated at USD 862.7 million in 2024 and is projected to reach USD 3,490.3 million by 2033, growing at a CAGR of 16.50% from 2025 to 2033. The market is driven due to the rising demand for adeno-associated virus (AAV) vectors in gene therapy applications, particularly in the treatment of rare genetic disorders, ophthalmic conditions, and neurological diseases.
Increasing approvals of AAV-based therapies by regulatory bodies have further accelerated the need for specialized manufacturing capacity. The market is primarily driven by thesurge in R&D investments in cell and gene therapy pipelines and is also fueling the reliance on AAV CDMOs. Small and mid-sized biotech firms often lack in-house vector development capabilities, making outsourcing a cost-effective and efficient solution. Leading CDMOs are expanding their capabilities by building advanced viral vector manufacturing facilities, integrating automated platforms, and offering end-to-end services including process development, GMP manufacturing, and regulatory support. This expansion of service portfolios is creating strong growth opportunities for the market.
To learn more about this report, request a free sample copy
Furthermore, strategic partnerships and capacity expansions by key players such as Lonza, Catalent, Thermo Fisher Scientific, and Samsung Biologics are enhancing market competitiveness. The growing prevalence of genetic and rare diseases, coupled with an increasing number of clinical trials evaluating AAV-based therapies, is further driving outsourcing demand. These dynamics position AAV CDMOs as a critical backbone of the gene therapy ecosystem, ensuring a timely supply of high-quality viral vectors for both clinical and commercial use.
Global AAV Contract Development And Manufacturing Organizations Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AAV contract development and manufacturing organizations market report based on workflow, culture, application, end use, and region.
- Workflow Outlook (Revenue, USD Million, 2021 - 2033)
- Upstream Processing
- Vector Amplification & Expansion
- Vector Recovery & Harvesting
- Downstream Processing
- Purification
- Fill Finish
- Culture Outlook (Revenue, USD Million, 2021 - 2033)
- Adherent Culture
- Suspension Culture
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Cell & Gene Therapy Development
- Vaccine Development
- Biopharmaceutical and Pharmaceutical Discovery
- Biomedical Research
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical and Biopharmaceutical Companies
- Academic & Research Institutes
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
Table of Contents
180 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. AAV Contract Development And Manufacturing Organizations Market: Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. AAV Contract Development And Manufacturing Organizations Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Technological Landscape
- 3.4. Pricing Model Analysis
- 3.5. AAV Contract Development And Manufacturing Organizations Market: Analysis Tools
- 3.5.1. Porter’s Five Forces Analysis
- 3.5.2. PESTEL Analysis
- Chapter 4. AAV Contract Development And Manufacturing Organizations Market: Workflow Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global AAV Contract Development And Manufacturing Organizations Market Workflow Movement Analysis
- 4.3. Global AAV Contract Development And Manufacturing Organizations Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
- 4.4. Upstream Processing
- 4.4.1. Upstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD million)
- 4.4.2. Vector Amplification & Expansion
- 4.4.2.1. Vector Amplification & Expansion Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Vector Recovery & Harvesting
- 4.4.3.1. Vector Recovery & Harvesting Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Downstream Processing
- 4.5.1. Downstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.2. Purification
- 4.5.2.1. Purification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.3. Fill Finish
- 4.5.3.1. Fill Finish Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. AAV Contract Development And Manufacturing Organizations Market: Culture Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global AAV Contract Development And Manufacturing Organizations Market Culture Movement Analysis
- 5.3. Global AAV Contract Development And Manufacturing Organizations Market Size & Trend Analysis, by Culture, 2021 to 2033 (USD Million)
- 5.4. Adherent Culture
- 5.4.1. Adherent Culture Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Suspension Culture
- 5.5.1. Suspension Culture Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. AAV Contract Development And Manufacturing Organizations Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global AAV Contract Development And Manufacturing Organizations Market Application Movement Analysis
- 6.3. Global AAV Contract Development And Manufacturing Organizations Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. Cell & Gene Therapy Development
- 6.4.1. Cell & Gene Therapy Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Vaccine Development
- 6.5.1. Vaccine Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Biopharmaceutical and Pharmaceutical Discovery
- 6.6.1. Biopharmaceutical and Pharmaceutical Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Biomedical Research
- 6.7.1. Biomedical Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. AAV Contract Development And Manufacturing Organizations Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global AAV Contract Development And Manufacturing Organizations Market End Use Movement Analysis
- 7.3. Global AAV Contract Development And Manufacturing Organizations Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 7.4. Pharmaceutical and Biopharmaceutical Companies
- 7.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Academic & Research Institutes
- 7.5.1. Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. AAV Contract Development And Manufacturing Organizations Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use
- 8.1. Regional Market Dashboard
- 8.2. Global Regional Market Snapshot
- 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 8.4. North America
- 8.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Competitive Scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Competitive Scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Competitive Scenario
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Europe
- 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Competitive Scenario
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Competitive Scenario
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Competitive Scenario
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Competitive Scenario
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Competitive Scenario
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Competitive Scenario
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Competitive Scenario
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Competitive Scenario
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Competitive Scenario
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Competitive Scenario
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8. MEA
- 8.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Competitive Scenario
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Competitive Scenario
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Competitive Scenario
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Competitive Scenario
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.6. Oman
- 8.8.6.1. Key Country Dynamics
- 8.8.6.2. Competitive Scenario
- 8.8.6.3. Regulatory Framework
- 8.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.7. Qatar
- 8.8.7.1. Key Country Dynamics
- 8.8.7.2. Competitive Scenario
- 8.8.7.3. Regulatory Framework
- 8.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. AAV Contract Development And Manufacturing Organizations Market Share Analysis, 2024
- 9.3. Company Profiles
- 9.3.1. Thermo Fischer Scientific, Inc.
- 9.3.1.1. Company overview
- 9.3.1.2. Financial performance
- 9.3.1.3. Product benchmarking
- 9.3.1.4. Strategic initiatives
- 9.3.2. Creative Biogene
- 9.3.2.1. Company overview
- 9.3.2.2. Financial performance
- 9.3.2.3. Product benchmarking
- 9.3.2.4. Strategic initiatives
- 9.3.3. Catalent Inc
- 9.3.3.1. Company overview
- 9.3.3.2. Financial performance
- 9.3.3.3. Product benchmarking
- 9.3.3.4. Strategic initiatives
- 9.3.4. Charles River Laboratories International, Inc
- 9.3.4.1. Company overview
- 9.3.4.2. Financial performance
- 9.3.4.3. Product benchmarking
- 9.3.4.4. Strategic initiatives
- 9.3.5. Danaher (Aldevron)
- 9.3.5.1. Company overview
- 9.3.5.2. Financial performance
- 9.3.5.3. Product benchmarking
- 9.3.5.4. Strategic initiatives
- 9.3.6. Forge Biologics
- 9.3.6.1. Company overview
- 9.3.6.2. Financial performance
- 9.3.6.3. Product benchmarking
- 9.3.6.4. Strategic initiatives
- 9.3.7. Genezen
- 9.3.7.1. Company overview
- 9.3.7.2. Financial performance
- 9.3.7.3. Product benchmarking
- 9.3.7.4. Strategic initiatives
- 9.3.8. ViroCell Biologics
- 9.3.8.1. Company overview
- 9.3.8.2. Financial performance
- 9.3.8.3. Product benchmarking
- 9.3.8.4. Strategic initiatives
- 9.3.9. Merck KGaA
- 9.3.9.1. Company overview
- 9.3.9.2. Financial performance
- 9.3.9.3. Product benchmarking
- 9.3.9.4. Strategic initiatives
- 9.3.10. VIRALGEN
- 9.3.10.1. Company overview
- 9.3.10.2. Financial performance
- 9.3.10.3. Product benchmarking
- 9.3.10.4. Strategic initiatives
- 9.3.11. Biovian Oy
- 9.3.11.1. Company overview
- 9.3.11.2. Financial performance
- 9.3.11.3. Product benchmarking
- 9.3.11.4. Strategic initiatives
- 9.3.12. Esco Lifesciences (Esco Aster Pte. Ltd.)
- 9.3.12.1. Company overview
- 9.3.12.2. Financial performance
- 9.3.12.3. Product benchmarking
- 9.3.12.4. Strategic initiatives
- 9.3.13. GenScript ProBio
- 9.3.13.1. Company overview
- 9.3.13.2. Financial performance
- 9.3.13.3. Product benchmarking
- 9.3.13.4. Strategic initiatives
- 9.3.14. Porton Advanced Solution Ltd
- 9.3.14.1. Company overview
- 9.3.14.2. Financial performance
- 9.3.14.3. Product benchmarking
- 9.3.14.4. Strategic initiatives
- 9.3.15. Ask Bio
- 9.3.15.1. Company overview
- 9.3.15.2. Financial performance
- 9.3.15.3. Product benchmarking
- 9.3.15.4. Strategic initiatives
- 9.3.16. Showa Denko
- 9.3.16.1. Company overview
- 9.3.16.2. Financial performance
- 9.3.16.3. Product benchmarking
- 9.3.16.4. Strategic initiatives
- 9.3.17. Takara Bio, Inc.
- 9.3.17.1. Company overview
- 9.3.17.2. Financial performance
- 9.3.17.3. Product benchmarking
- 9.3.17.4. Strategic initiatives
- 9.3.18. ABL Manufacturing
- 9.3.18.1. Company overview
- 9.3.18.2. Financial performance
- 9.3.18.3. Product benchmarking
- 9.3.18.4. Strategic initiatives
- 9.3.19. Oxford Biomedica
- 9.3.19.1. Company overview
- 9.3.19.2. Financial performance
- 9.3.19.3. Product benchmarking
- 9.3.19.4. Strategic initiatives
- 9.3.20. Belief Biomed, Inc.
- 9.3.20.1. Company overview
- 9.3.20.2. Financial performance
- 9.3.20.3. Product benchmarking
- 9.3.20.4. Strategic initiatives
- 9.3.21. Beijing Anlong Biomedicine Co., Ltd
- 9.3.21.1. Company overview
- 9.3.21.2. Financial performance
- 9.3.21.3. Product benchmarking
- 9.3.21.4. Strategic initiatives
- 9.3.22. Forecyte Bio Limited
- 9.3.22.1. Company overview
- 9.3.22.2. Financial performance
- 9.3.22.3. Product benchmarking
- 9.3.22.4. Strategic initiatives
- 9.3.23. Gene Pharma, Inc.
- 9.3.23.1. Company overview
- 9.3.23.2. Financial performance
- 9.3.23.3. Product benchmarking
- 9.3.23.4. Strategic initiatives
- 9.3.24. Skyline Therapeutics
- 9.3.24.1. Company overview
- 9.3.24.2. Financial performance
- 9.3.24.3. Product benchmarking
- 9.3.24.4. Strategic initiatives
- 9.3.25. TFBS Bioscience, Inc
- 9.3.25.1. Company overview
- 9.3.25.2. Financial performance
- 9.3.25.3. Product benchmarking
- 9.3.25.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.